Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 2017 Jan 25;55(2):510–518. doi: 10.1128/JCM.01853-16

Comparative Evaluation of Four Phenotypic Tests for Detection of Carbapenemase-Producing Gram-Negative Bacteria

Audrey Noël 1, Te-Din Huang 1,, Catherine Berhin 1, Martin Hoebeke 1, Warda Bouchahrouf 1, Sami Yunus 1, Pierre Bogaerts 1, Youri Glupczynski 1
Editor: Karen C Carroll2
PMCID: PMC5277521  PMID: 27927915

ABSTRACT

Four screening assays aimed for rapid detection of carbapenemase production from Gram-negative bacterial isolates, i.e., the Neo-Rapid Carb kit (Rosco Diagnostica A/S), the Rapidec Carba NP test (bioMérieux SA), the β Carba test (Bio-Rad Laboratories N.V.), and a homemade electrochemical assay (BYG Carba test) were evaluated against a panel comprising 328 clinical isolates (Enterobacteriaceae [n = 198] and nonfermentative Gram-negative bacilli [n = 130]) with previously characterized resistance mechanisms to carbapenems. Among Enterobacteriaceae isolates, the BYG Carba test and the β Carba test showed excellent sensitivities (respectively, 100% and 97.3%) and specificities (respectively, 98.9% and 97.7%). The two other assays yielded poorer performances with sensitivity and specificity of 91.9% and 83.9% for the Rapidec Carba NP test and of 89.2% and 89.7% for the Neo-Rapid Carb kit, respectively. Among Pseudomonas spp., sensitivities and specificities ranged, respectively, from 87.3% to 92.7% and from 88.2% to 94.1%. Finally, all tests performed poorly against Acinetobacter spp., with sensitivities and specificities, respectively, ranging from 27.3% to 75.8% and from 75 to 100%. Among commercially available assays, the β Carba test appeared to be the most convenient for routine use and showed the best overall performances, especially against OXA-48-like producers. The excellent performance of the BYG Carba test against Enterobacteriaceae was confirmed (100% sensitivity and 98.9% specificity).

KEYWORDS: Acinetobacter, CPE, Pseudomonas, antibiotic resistance, carbapenem hydrolysis, carbapenemase screening

INTRODUCTION

During the last decade, the emergence of carbapenemase-producing Gram-negative bacteria has become a major public health issue. These multidrug-resistant organisms can only be treated by limited therapeutic options and have been widely involved in nosocomial outbreaks (1, 2). Rapid detection is of paramount importance for prompt implementation of appropriate antimicrobial therapy and of isolation procedures in order to prevent cross-transmission to other patients.

A large variety of acquired carbapenem-hydrolyzing β-lactamases have spread worldwide (2, 3). Currently the most prevalent carbapenemases in Enterobacteriaceae in Europe belong to the Ambler class A (KPC), class B (VIM, IMP, and NDM), and class D (OXA-48-like) (2, 4). In Acinetobacter spp., carbapenem-hydrolyzing β-lactamases essentially belong to the Ambler class D, the most prevalent variants being OXA-23-, OXA-24-, and OXA-58-like enzymes (3, 5), while class B metallo-β-lactamases (MBL), mainly VIM and IMP to a lesser extent, are the most frequently encountered among Pseudomonas spp. (3, 6). Several phenotypic assays developed to detect carbapenemase production from bacterial culture within hours are now commercially available, including the Neo-Rapid Carb kit (NRCK) (Rosco Diagnostica A/S, Taastrup, Denmark), the Rapidec Carba NP test (RCNP) (bioMérieux SA, Marcy l'Etoile, France), and the recently marketed β Carba test (BCT) (Bio-Rad Laboratories N.V., Marnes-la-Coquette, France). In addition, we recently developed and validated the BYG Carba test (BYG), an in-house rapid electrochemical assay which allows objective detection (positivity based on a cutoff value) of carbapenemase-producing Enterobacteriaceae (CPE) from bacterial culture colonies in less than 30 min (7).

The Neo-Rapid Carb kit and the Rapidec Carba NP test have been evaluated by several groups (816), but, to our knowledge, no comparison with the novel β Carba test has been published yet. Evaluations of the colorimetric carbapenem hydrolysis assays have mostly focused on Enterobacteriaceae, while reports dealing with nonfermentative Gram-negative bacilli are scarce.

The aim of this study was to compare prospectively the analytical performances and qualitative characteristics (turnaround time, ease of interpretation of results, and costs) of these screening assays for the detection of the most prevalent CPE isolates. We also evaluated their performance against that of a selected panel of collection isolates of Pseudomonas spp. and Acinetobacter spp. that had been previously characterized for their resistance mechanisms to β-lactams.

RESULTS

Tests results for Enterobacteriaceae and nonfermentative Gram-negative isolates are presented in Tables 1 and 2, respectively. All Enterobacteriaceae isolates showing discrepant results with at least one of the four assays are listed and detailed in Table S1 in the supplemental material.

TABLE 1.

Evaluation of the BYG Carba test, β Carba test, Rapidec Carba NP test, and Neo-Rapid Carb screen test against 198 Enterobacteriaceae isolates

Enterobacteriaceae group Resistance mechanism No. of isolates MIC range (μg/ml) for:
Test results (no.) fora:
Meropenem Imipenem Ertapenem BYG
BCT
RCNP
NRCK
P N P D N P D N NI P D N NI
CPE KPC-3 8 4–>32 16–>32 12–>32 8 0 7 1 0 8 0 0 0 8 0 0 0
NDM-1 18 3–>32 2–>32 6–>32 18 0 18 0 0 18 0 0 0 18 0 0 0
VIMb 13 1–32 4–>32 0.19–>32 13 0 13 0 0 13 0 0 0 13 0 0 0
OXA-48 69 0.19–>32 0.38–>32 0.25–>32 69 0 67 2 0 60 9 0 0 57 9 2 1
NDM-1 + OXA-48 2 >32 >32 >32 2 0 2 0 0 2 0 0 0 2 0 0 0
KPC-2 + VIM-1 1 >32 >32 >32 1 0 1 0 0 1 0 0 0 1 0 0 0
Total CPE 111 0.19–>32 0.38–>32 0.19–>32 111 0 108 3 0 102 9 0 0 99 9 2 1
Non-CPE ESBL 29 0.016–24 0.125–3 0.006–>32 0 29 0 0 29 0 6 23 0 0 2 26 1
AmpC overexpression 30 0.023–12 0.125–32 0.19–>32 1 29 0 1 29 0 5 25 0 0 1 25 4
ESBL and AmpC overexpression 13 0.047–4 0.19–16 0.094–>32 0 13 0 0 13 0 2 11 0 0 1 12 0
Narrow spectrum β-lactamases 15 0.012–4 0.19–2 0.003–24 0 15 0 1 14 0 1 14 0 0 0 15 0
Total non-CPE 87 0.012–24 0.125–32 0.003–>32 1 86 0 2 85 0 14 73 0 0 4 78 5
a

BYG, BYG Carba test, BCT, β Carba test, RCNP, Rapidec Carba NP test, NRCK, Neo-Rapid Carb screen kit; P, positive; N, negative; D, doubtful; NI, noninterpretable.

b

VIM-1 (n = 12), VIM-4 (n = 1).

TABLE 2.

Evaluation of the BYG Carba test, β Carba test, Rapidec Carba NP test, and Neo-Rapid Carb screen kit against 130 isolates of nonfermenting Gram-negative bacteria

Genus Carbapenemase No. of isolates MIC range (μg/ml) for:
Test results (no.) fora:
Meropenem Imipenem BYG
BCT
RCNP
NRCK
P N P D N P D N NI P D N NI
Pseudomonas spp. GESb 4 >32 16–>32 1 3 0 0 4 2 0 2 0 2 0 2 0
KPC-2 1 >32 >32 1 0 1 0 0 1 0 0 0 1 0 0 0
VIMc 34 32–>32 32–>32 32 2 34 0 0 32 0 2 0 33 0 0 1
IMPd 11 24–>32 >32 10 1 11 0 0 11 0 0 0 11 0 0 0
NDM-1 1 >32 >32 1 0 1 0 0 1 0 0 0 0 0 0 1
GIM 1 >32 >32 1 0 1 0 0 1 0 0 0 1 0 0 0
DIM 1 >32 >32 1 0 1 0 0 1 0 0 0 1 0 0 0
SPM-1 1 >32 >32 1 0 1 0 0 1 0 0 0 1 0 0 0
OXA-198 1 12 >32 0 1 0 1 0 0 0 1 0 1 0 0 0
Total carbapenemase producers 55 12–>32 16–>32 48 7 50 1 4 50 0 5 0 51 0 2 2
Non-carbapenemase producerse 34 0.38–>32 0.75–>32 2 32 2 0 32 1 2 30 1 0 1 30 3
Acinetobacter spp. GES-14 1 32 32 0 1 0 0 1 0 0 1 0 0 0 1 0
VIM-4 1 32 >32 1 0 1 0 0 1 0 0 0 1 0 0 0
IMPf 3 16–>32 3–>32 3 0 3 0 0 3 0 0 0 3 0 0 0
NDM-1 2 >32 >32 2 0 1 1 0 2 0 0 0 1 1 0 0
GIM 1 8 4 1 0 1 0 0 1 0 0 0 1 0 0 0
OXA carbapenemasesg 22 2–>32 4–>32 15 7 16 3 3 2 3 17 0 2 1 18 1
NDM-1 + OXA-23 1 >32 >32 1 0 1 0 0 1 0 0 0 0 0 1 0
NDM-2 + OXA-23 1 >32 >32 1 0 1 0 0 1 0 0 0 1 0 0 0
VIM-4 + OXA-58 1 32 >32 0 1 1 0 0 1 0 0 0 0 0 1 0
Total carbapenemase producers 33 2–>32 3–>32 24 9 25 4 4 12 3 18 0 9 2 21 1
Non-carbapenemase producersh 8 0.25–32 0.19–8 0 8 1 0 7 0 2 6 0 0 0 8 0
a

BYG, BYG Carba test, BCT, β Carba test, RCNP, Rapidec Carba NP test, NRCK, Neo-Rapid CARB screen kit; P, positive; N, negative; D, doubtful; NI, noninterpretable.

b

GES-2 (n = 1), GES-5 (n = 1), GES-18 (n = 2).

c

VIM-1 (n = 2), VIM-2 (n = 24), VIM-4 (n = 7), VIM-5 (n = 1).

d

Including IMP-1 (n = 1), IMP-2 (n = 1), IMP-7 (n = 1), IMP-13 (n = 5), IMP-15 (n = 1), IMP-19 (n = 1), and IMP-29 (n = 1).

e

Including strains producing BEL-1 (n = 2), BEL-2 (n = 1), GES-1 (n = 2), OXA-2 (n = 1), OXA-2a (n = 1), OXA-4 (n = 1), OXA-9 (n = 1), OXA-10 (n = 1), OXA-18 (n = 1), OXA-28 (n = 1), OXA-35 (n = 1), PME-1 (n = 1), SHV-2a (n = 1), SHV-5 (n = 1), TEM-4 (n = 1), combination of OXA-10 + TEM-1 (n = 1), and phenotypically assessed impermeability alone (n = 16).

f

Including IMP-1 (n = 1), IMP-4 (n = 1), and IMP-14 (n = 1).

g

Including OXA-23 (n = 10), OXA-24 (n = 1), OXA-25 (n = 1), OXA-26 (n = 1), OXA-27 (n = 1), OXA-58 (n = 4), OXA-72 (n = 1), OXA-143 (n = 1), OXA-255 (n = 1), and combination of OXA-23 with OXA-58 (n = 1).

h

Including strains producing CARB-5 (n = 1), CARB-10 (n = 1), GES-12 (n = 1), PER-1 (n = 1), VEB-1 (n = 1), phenotypically assessed impermeability (n = 1), and wild type (n = 2).

Among the 198 Enterobacteriaceae isolates referred, 111 (56.1%) produced a carbapenemase, including OXA-48 (n = 69), NDM-1 (n = 18), VIM-1 (n = 12), KPC-3 (n = 8), VIM-4 (n = 1), and combinations of OXA-48 plus NDM-1 (n = 2) and of KPC-2 plus NDM-1 (n = 1). Various genus and species were included, i.e., Klebsiella pneumoniae (n = 104), Enterobacter cloacae (n = 32), Escherichia coli (n = 31), Citrobacter freundii (n = 9), Enterobacter aerogenes (n = 9), Klebsiella oxytoca (n = 8), Citrobacter koseri (n = 2), Serratia marcescens (n = 2), and Enterobacter asburiae (n = 1).

Of the 111 confirmed CPE isolates, 108 (97.3%), 102 (91.9%), 99 (89.2%), and 111 (100%) were correctly assigned by BCT, RCNP, NRCK, and BYG, respectively. Among the 87 carbapenemase-negative isolates, 85 (97.7%), 73 (83.9%), 78 (89.7%), and 86 (98.9%) were correctly identified as non-CPE by BCT, RCNP, NRCK, and BYG, respectively. BCT yielded doubtful results for three CPE isolates (OXA-48 [n = 2] and KPC-3 [n = 1]) and for two non-CPE isolates (one K1-OXY overexpressing K. oxytoca susceptible to all carbapenems and one E. cloacae overexpressing AmpC combined with a porin deficiency resistant to ertapenem). For RCNP, 9 OXA-48-producing isolates and 14 non-CPE isolates belonging to various species and harboring diverse and unrelated resistance mechanisms induced a doubtful color shift. Using NRCK, 2, 9, and 1 OXA-48-producing strains gave false-negative, doubtful, and noninterpretable results, respectively, while 9 non-CPE strains generated either doubtful (n = 4) or noninterpretable (n = 5) results. The BYG yielded only one false-positive result for one carbapenem-susceptible DHA-producing K. pneumoniae.

Of the 55 carbapenemase-producing Pseudomonas spp., 50 (90.9%), 50 (90.9%), 51 (92.7%), and 48 (87.2%) were accurately detected by BCT, RCNP, NRCK, and BYG, respectively. BCT failed to detect any GES-type carbapenemases (n = 4) and yielded a doubtful result for one OXA-198 (class D carbapenemase)-producing P. aeruginosa, while false-positive results were obtained for two carbapenem-resistant carbapenemase-negative strains (one OXA-35 producing P. aeruginosa and one P. aeruginosa with phenotypically assessed impermeability alone). RCNP missed carbapenemase detection for 5 Pseudomonas species isolates (VIM-2, VIM-4, GES-2, GES-18, and OXA-198 [n = 1 each]). One noninterpretable result, two doubtful results, and one false-positive (i.e., OXA-10-producing P. aeruginosa) result were recorded among the carbapenemase-negative isolates. NRCK yielded two false-negative results for a GES-2 (n = 1)-producing isolate and a GES-5 (n = 1)-producing isolate as well as two noninterpretable results. Regarding non-carbapenemase-producing isolates, three noninterpretable results and one doubtful result, i.e., a BEL-1 extended-spectrum β-lactamase (ESBL)-producing P. aeruginosa, were observed. Using the BYG, false-negative results were observed for 7 isolates (GES-type carbapenemases [n = 3], VIM-2 [n = 2], IMP-2 [n = 1], and OXA-198 [n = 1]), while false-positive results were recorded for two BEL-1-producing Pseudomonas species isolates.

Finally, out of 33 carbapenemase-producing Acinetobacter species isolates, 25 (75.8%), 12 (36.4%), 9 (27.3%), and 24 (72.7%) were correctly identified by BCT, RCNP, NRCK, and BYG, respectively. BCT yielded four doubtful color shift and four false-negative results involving class D carbapenemase producers (OXA-23, OXA-24, or OXA-58 variants [n = 6]), GES-14 (n = 1), and NDM-1 (n = 1), as well as one false-positive result for a GES-12-producing strain. RCNP failed to detect 20 class D carbapenemase producers and one GES-14-producing Acinetobacter baumannii isolate, while doubtful results were documented for 2 carbapenemase-negative carbapenem-susceptible A. baumannii isolates. NRCK also missed most OXA-type carbapenemase-producing strains. The assay also yielded doubtful color shifts for one OXA-143- and one NDM-1-producing Acinetobacter species isolate. No false-positive result and one single noninterpretable test were encountered. Last, the BYG Carba test yielded 9 false-negative results (OXA-type [n = 8] and GES-type [n = 1] carbapenemase) but no false-positive result.

The analytical performances for each test are summarized in Table 3. For Enterobacteriaceae, sensitivities ranged from 89.2% (NRCK) to 100% (BYG), while specificities varied between 83.9% (RCNP) and 98.9% (BYG). Slightly lower performances were obtained for Pseudomonas spp. with sensitivities and specificities ranging between 87.3% (BYG) and 92.7% (NRCK) and between 88.2% (RCNP and NRCK) and 94.1% (BYG and BCT), respectively. On the other hand, for Acinetobacter spp., analytical performances were on the whole insufficient with sensitivities below 80% for all 4 assays.

TABLE 3.

Analytical performances of the BYG Carba test, β Carba test, Rapidec Carba NP test, and Neo-Rapid Carb screen kit

Parametera Results forb:
BYG BCT RCNP NRCK
Enterobacteriaceae (n = 198)
    Sensitivity (%) 100 97.3 91.9 89.2
    95% CI 100–100 93.4–100 85.4–98.4 81.8–96.6
    Specificity (%) 98.9 97.7 83.9 89.7
    95% CI 96–100 93.7–100 74.1–93.8 81.5–97.8
    PPV (%) 99.1 98.2 87.9 91.7
    95% CI 96.9–100 95–100 80.4–95.5 85–98.3
    NPV (%) 100 96.6 89 86.7
    95% CI 100–100 91.8–100 80.4–97.7 77.7–95.6
Pseudomonas spp. (n = 89)
    Sensitivity (%) 87.3 90.9 90.9 92.7
    95% CI 76–98.5 81.2–100 81.2–100 84–100
    Specificity (%) 94.1 94.1 88.2 88.2
    95% CI 84–100 84–100 74.4–100 74.4–100
Acinetobacter spp. (n = 41)
    Sensitivity (%) 72.7 75.8 36.4 27.3
    95% CI 53.3–92.1 57.1–94.4 15.4–57.3 7.9–46.7
    Specificity (%) 100 87.5 75 100
    95% CI 100–100 58.3–100 36.7–100 100–100
a

CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.

b

BYG, BYG Carba test, BCT, β Carba test, RCNP, Rapidec Carba NP test, NRCK, Neo-Rapid CARB screen kit.

The results of the reproducibility assessment on 20 strains are detailed in Table S2 in the supplemental material. Overall, the interassay/interoperator reproducibility rates were, respectively, 90%/85% for BCT, 100%/100% for RCNP, 95%/90% for NRCK, and 95%/95% for BYG. Besides the false-negative results for each of the four assays, Acinetobacter species isolates were responsible for the majority of the discrepancies, confirming the poor performance of the assays in this group. Additionally, a second false-positive result using BCT with a non-carbapenemase-producing carbapenem-resistant K. oxytoca isolate was documented. This strain induced a color variation ranging from dark yellow (negative) to orange (positive). Of note, one OXA-48 K. pneumoniae isolate gave a doubtful result three times with RCNP, and one DHA-producing K. pneumoniae yielded one noninterpretable result with NRCK. With regard to the BYG test, after exclusion of the Acinetobacter species isolates, all strains tested gave positive results with intensity signals that were clearly above the defined cutoff of 11.5 arbitrary units (AU) (range, 25.9 to 134.1 AU), with a mean within-strain coefficient of variation (CV) of 20.1%.

DISCUSSION

BCT, RCNP, and NRCK are three rapid colorimetric assays that have been recently commercialized for the screening of carbapenemase-producing bacterial isolates. They share several advantages over in-house assays such as ready-to-use reagents and the quality control process guaranteed by the manufacturer. The BYG Carba test requires a specific testing device and is not commercially available yet but presents the advantage over the colorimetric assays of objective unequivocal results. A new BYG procedure eliminating several steps, including the preparation of a bacterial suspension and of the lysis step, was used. This simplified protocol (version 2.0) was previously validated in our laboratory comparatively to the original protocol against 207 Enterobacteriaceae isolates and yielded excellent performances (sensitivity, 99.3%; specificity, 99.1%) (17).

BCT and the BYG Carba test displayed excellent performances for the detection of the most prevalent carbapenemase-producing Enterobacteriaceae with remarkably high negative predictive values (>95%), emphasizing that a negative result by these tests may almost exclude the presence of carbapenemase and prevent further unnecessary testing on such isolates. However, results for testing of K. oxytoca with BCT should be taken with caution because false-positive results have been documented.

On the other hand, the calculated analytical performances of RCNP and NRCK were lower than previously reported (9, 11, 14, 16). At least two reasons might have accounted for those differences. First, the distribution of carbapenemase types among CPE isolates comprised a larger proportion of OXA-48 producers (62.2%) that are known to be less well detected by these two assays (8, 10, 12, 14). However, this high proportion of OXA-48 producers is in line with the current epidemiology of CPE observed in several European countries such as Belgium, France, Spain, or Germany (4). In comparison with this report, OXA-48 producers represented only 7.9% to 27.5% of the screened CPE isolates in other studies where better overall tests performances were reported (11, 13, 14, 16).

The second explanation might relate to the way we categorized doubtful results that were more frequently observed with RCNP and NRCK despite intense preliminary training of the operators. Repetition of doubtful tests with higher inocula had been suggested to partially solve the problem (11, 12) but was not performed here as we considered that it would lead to a delay in reporting of the results besides increasing the costs. Unlike others, we decided to classify these results as false (either false positive or false negative), since, in the routine of a clinical microbiology laboratory, only unequivocal results would be transmitted to clinicians. Visual interpretation of faint color variations such as “red-orange,” “dark,” or “pale” orange may vary from one observer to another and might impact analytical performances. Reporting doubtful results as false highlights the limitations of eye-read colorimetric tests and the potential benefits of optical reading device development. BYG has the clear advantage of being quantitative and objective, the results being automatically generated in real time by internal software once the positivity cutoff is crossed by the monitored signal curve.

All four assays accurately detected carbapenemase-producing Pseudomonas spp. but yielded suboptimal performances for Acinetobacter spp. Detection of carbapenemase production in Acinetobacter spp. is for known for being more difficult, probably due to the very low carbapenem hydrolytic activities of the class D hydrolyzing β-lactamases found in these organisms (3, 18). Further evaluation of modified procedures, including increasing incubation time, inoculum preparation, and lysis might be useful for improving test performances.

Overall, BCT showed better performances for the detection of class D carbapenemases than the two other commercial assays. Indeed, BCT allowed the unambiguous detection of 97.1% of the 69 OXA-48-producing Enterobacteriaceae isolates, compared to only 87% and 82.6% for RCNP and NRCK, respectively.

Among the 22 class D carbapenemase-producing Acinetobacter species isolates, carbapenemase activity was detected in 72.7%, 9.1%, and 9.1%, respectively, using BCT, RCNP, and NRCK. Moreover, all four assays performed poorly for the detection of GES carbapenemases, again most probably because of the weak carbapenem hydrolytic activity of many variants belonging to this carbapenemase family.

The most salient technical characteristics of the four tests are compared in Table 4. ΒCT is a one-step assay that yields a result after a single 30-min incubation period. On the whole, the use of RCNP and of NRCK required more handling and incubation steps, resulting in slightly longer turnaround time. BCT requires a fully charged 1-μl loop. The bacterial inoculum size is at least two times larger for both NRCK and RNCP, which may require in some instances an additional subculture before the test can be performed. According to the manufacturer's instructions, BCT and NRCK have to be performed on fresh isolates, while RCNP may be performed on bacterial colonies aged up to 72 h. BCT was the less reproducible assay mainly due to discrepant results with Acinetobacter spp. The large number of doubtful results was an important issue for RCNP, while noninterpretable tests were more frequently documented using NRCK.

TABLE 4.

Technical characteristics of BYG Carba test, β Carba test, Rapidec Carba NP test, and Neo-Rapid Carb screen kit

Characteristic Results fora:
BYG BCT RCNP NRCK
Validated group of isolates (or recommended by manufacturer) Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae Enterobacteriaceae
P. aeruginosa P. aeruginosa P. aeruginosa
A. baumannii
Maximal incubation time (min) 60 30 160 90
Total hands-on time (min) 5 2 4 6
No. of handling steps 1 1 3 2
Ease of use Easy, little training required Very easy, no training required Easy, little training required Easy, little training required
Catalog price per unit test in Belgium Not commercially available 6.6 USDb 8.8 USD 2.4 USD
Positive criteria Signal attaining a fixed cutoff Orange, red, purple Orange-red to yellow, with a red negative control Orange to yellow, with a red negative control
Overall doubtful results (%)c 0 3 9.1 4.9
Overall noninterpretable resultsc NRd NR 0.3 3.4
Overall reproducibility (%)e 95 85 100 90
a

BYG, BYG Carba test, BCT, β Carba test, RCNP, Rapidec Carba NP test, NRCK, Neo-Rapid CARB screen kit.

b

USD, U.S. dollars.

c

Proportion of doubtful and noninterpretable results among all tested isolates.

d

NR, not reportable as no internal negative control is provided with the test.

e

Proportion of isolates showing full agreements when tested in triplicate in a reproducibility evaluation (total n = 20).

BYG requires a single handling step and yields a result after a 30-min running period when screening for CPE and after 60 min when screening for carbapenemase in Gram-negative nonfermenters. This test only requires one to three colonies, which may represent an advantage, especially in a primary culture of a clinical specimen growing a lower number of colonies or a mixture of different colonies.

There are limitations to our study. First, we acknowledge the limited diversity of carbapenemase types present in the Enterobacteriaceae isolates routinely collected which, however, reflects the current epidemiological patterns in Belgium, largely dominated by OXA-48 CPE. Hence, the analytical performances of these tests should be assessed in geographical areas with different epidemiological settings. A second limitation is related to the possible repeated inclusion of single epidemic clones, although in the present study the isolates were referred from a large number of different laboratories throughout Belgium, suggesting at the least a certain level of diversity among the strains tested.

In conclusion, BCT, RCNP, and NRCK are three rapid commercial assays for the screening of carbapenemase among Gram-negative bacteria. Some difficulties of interpretations were encountered with RCNP and NRCK when dealing with OXA-48-producing Enterobacteriaceae. BCT appeared on the whole to perform the best, being also the easiest test to perform and to interpret and providing reliable results in short processing times among Enterobacteriaceae (with caution required for K. oxytoca isolates) and Pseudomonas spp. None of the assays was considered to perform sufficiently well against Acinetobacter spp., for which improvements are clearly required before recommending their usage. The in-house BYG appears promising since it provides quantitative, traceable (electronic data reporting), and rapid accurate results using a minimal amount of bacteria. BYG allowed accurate detection of CPE but could still be improved for the detection of carbapenemases in nonfermenters.

MATERIALS AND METHODS

Bacterial isolates.

A total of 198 nonduplicate, consecutive Enterobacteriaceae isolates referred by 56 microbiology laboratories to the National Reference Center (NRC) (CHU UCL Namur, Belgium) from December 2015 to February 2016 for confirmation of carbapenemase production were included (the selection criteria for referral were based on decreased susceptibility to at least one carbapenem using local routine methods and interpreted according to either EUCAST or CLSI recommendations). For the evaluation of nonfermentative Gram-negative bacilli (NF), 130 collection strains of Pseudomonas spp. (n = 89, including 55 carbapenemase producers) and of Acinetobacter spp. (n = 41, including 33 carbapenemase producers) were analyzed. The majority of the collection strains originated from the Belgian NRC, but some isolates were obtained from the French and from the German reference centers (see Acknowledgments). They were all characterized for their carbapenemase content by PCR and sequencing (Tables 1 and 2).

Strain characterization.

Clinical isolates were subcultured overnight on Trypticase soy agar II with 5% sheep blood (TSA + SB) plates (Becton, Dickinson and Company, NJ, USA) to obtain fresh colonies for further investigation. Collection strains stored at −80°C were thawed and subcultured twice on the same culture media before testing.

Bacterial identification was confirmed by matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry (Microflex LT; Bruker Daltonik GmbH, Bremen, Germany) using Bruker Biotyper 2.2 software. Patterns of resistance mechanisms to β-lactams were determined by the disk diffusion method. MICs were determined for ertapenem, imipenem, and meropenem using Etests (bioMérieux SA, Marcy l'Etoile, France) on Mueller-Hinton II agar plates (Becton Dickinson, Aalst, Belgium). Results were interpreted according to CLSI 2015 guidelines (19).

The most prevalent carbapenemases encountered in Enterobacteriaceae and nonfermenters were sought by two in-house ISO15189-certified multiplex PCRs targeting blaOXA-48, blaNDM, blaKPC, blaVIM and blaIMP, and blaOXA-23, blaOXA-24, and blaOXA-58 (20). Further molecular detections targeting other less prevalent carbapenemases were only performed in case of result discrepancies between phenotypic hydrolysis-based assays (positive/doubtful results) and molecular tests (negative by the two PCRs). Finally, carbapenemase genes were sequenced using external Sanger sequencing services (Macrogen, Seoul, South Korea) for allele identification.

Testing procedure for commercial carbapenemase detection assays.

The Rapidec Carba NP (RCNP) and Neo-Rapid Carb kit (NRCK), a variant of the former test, are based on imipenem hydrolysis detection using the pH indicator red phenol that turns from red to yellow in the presence of carbapenem-hydrolyzing enzymes (21). The β Carba test (BCT) is based on the opposite color shift from yellow to orange, red, or purple of an undisclosed chromogenic carbapenem substrate in the presence of carbapenem-hydrolyzing enzymes. The BYG Carba test (BYG) is an electrochemical assay that detects the increase of conductivity of a polyaniline-coated electrode, which is highly sensitive to modification of pH and of redox activity occurring during the imipenem enzymatic hydrolysis reaction (7).

All four screening tests (BCT, RCNP, NRCK, and BYG) were simultaneously and blindly performed on fresh isolates. Colorimetric assays were processed and interpreted according to the manufacturer's instructions (2224). Identical procedures were applied for testing Enterobacteriaceae and NF. For the BYG Carba test, a simplified procedure recently validated in our laboratory was used in the present study (BYG protocol version 2.0) (17). Briefly, one to three colonies are directly spotted on two adjacent working probes of the BYG test electrode to cover the entire sensor surface. The electrode is then recovered with 50 μl of a homemade buffer with or without 3 mg/ml imipenem (6 mg/ml of Tienam, containing 3 mg/ml imipenem monohydrate and 3 mg/ml cilastatin sodium; MSD France, Courbevoie, France). A signal intensity cutoff of 11.5 arbitrary units (AU) was chosen for the discrimination between carbapenemase and non-carbapenemase producers according to the validation of the BYG 2.0 protocol (17).

Twenty strains (10 Enterobacteriaceae and 10 NF) covering different species and resistance mechanisms were further tested in triplicate (twice by one operator and a third time by another operator) to evaluate interassay and interoperator reproducibility rates. Interassay/interoperator reproducibility rates were calculated by dividing the number of intraoperator/interoperator agreements by the number of strains tested.

Test interpretation and performance analysis.

Results were blindly interpreted by a well-trained operator and recorded as positive (P), negative (N), doubtful (D), and noninterpretable (NI).

BCT was interpreted as positive if the color shifted from yellow to orange, red, or purple. For the two others colorimetric assays (RCNP and NRCK), a change from red to orange or yellow was considered positive.

Results were recorded as doubtful if the operator could not categorize the test either as positive or negative and noninterpretable whenever the negative control showed a color shift. Since there is no negative control for BCT, no noninterpretable result could be recorded for this assay. For BYG, only positive or negative results were recorded, depending on whether the measured signal curve crosses the settled cutoff or not. Doubtful and noninterpretable tests were not repeated, and these results were considered together either as false positive or as false negative in the calculation of the performance parameters.

Statistical analysis was performed using the SISA website (D. G. Uitenbroek; http://www.quantitativeskills.com/sisa/distributions/binomial.htm). A width of 95% was chosen for the confidence interval. Sensitivity and specificity for each test compared to those for molecular detection were calculated separately for Enterobacteriaceae, Pseudomonas spp., and Acinetobacter spp. The positive predictive value (PPV) and the negative predictive value (NPV) were also calculated for each test for the consecutive Enterobacteriaceae clinical isolates that were prospectively referred to our laboratory, considering PCR sequencing results as the gold standard.

Supplementary Material

Supplemental material

ACKNOWLEDGMENTS

We are grateful to our microbiologist colleagues for referring the isolates to the national reference center. We also thank G. Cuzon and T. Naas (CHU Bicêtre, France), K. Jeannot and P. Plésiat (CHU Besançon, France), and M. Kaase (Bochum, Germany) for supplying some of the isolates tested in this study.

The Rapidec Carba NP and β Carba kits used for evaluation among Enterobacteriaceae were provided, respectively, by bioMérieux and by Bio-Rad. NRCK kits from Rosco Diagnostica were purchased on the market.

The national reference center is partially supported by the Belgian Ministry of Social Affairs through a fund within the health insurance system.

S.Y. is the inventor for BYG technology patents (application no. PCT/EP2012/073011), and S.Y. and P.B. are the inventors for patent pending application no. 14773161.2.

Footnotes

Supplemental material for this article may be found at https://doi.org/10.1128/JCM.01853-16.

REFERENCES

  • 1.Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791–1798. doi: 10.3201/eid1710.110655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Cantón R, Akova M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, Samuelsen O, Seifert H, Woodford N, Nordmann P. 2012. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 18:413–431. doi: 10.1111/j.1469-0691.2012.03821.x. [DOI] [PubMed] [Google Scholar]
  • 3.Diene SM, Rolain JM. 2014. Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species. Clin Microbiol Infect 20:831–838. doi: 10.1111/1469-0691.12655. [DOI] [PubMed] [Google Scholar]
  • 4.Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL, European Survey of Carbapenemase-Producing Enterobacteriaceae Working Group. 2015. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill 20(45):pii=30062 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21300. [DOI] [PubMed] [Google Scholar]
  • 5.Kempf M, Rolain JM. 2012. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 39:105–114. doi: 10.1016/j.ijantimicag.2011.10.004. [DOI] [PubMed] [Google Scholar]
  • 6.Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN. 2014. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009−11 in 14 European and Mediterranean countries. J Antimicrob Chemother 69:1804–1814. doi: 10.1093/jac/dku048. [DOI] [PubMed] [Google Scholar]
  • 7.Bogaerts P, Yunus S, Massart M, Huang TD, Glupczynski Y. 2016. Evaluation of the BYG Carba test, a new electrochemical assay for rapid laboratory detection of carbapenemase-producing Enterobacteriaceae. J Clin Microbiol 54:349–358. doi: 10.1128/JCM.02404-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Huang TD, Berhin C, Bogaerts P, Glupczynski Y. 2014. Comparative evaluation of two chromogenic tests for rapid detection of carbapenemase in Enterobacteriaceae and in Pseudomonas aeruginosa isolates. J Clin Microbiol 52:3060–3063. doi: 10.1128/JCM.00643-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Poirel L, Nordmann P. 2015. Rapidec Carba NP test for rapid detection of carbapenemase producers. J Clin Microbiol 53:3003–3008. doi: 10.1128/JCM.00977-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Gallagher LC, Roundtree SS, Lancaster DP, Rudin SD, Bard JD, Roberts AL, Marshall SH, Bonomo RA, Sullivan KV. 2015. Performance of the CLSI Carba NP and the Rosco Carb screen assays using North American carbapenemase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates. J Clin Microbiol 53:3370–3373. doi: 10.1128/JCM.01547-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.AbdelGhani S, Thomson GK, Snyder JW, Thomson KS. 2015. Comparison of the Carba NP, modified Carba NP, and updated Rosco Neo-Rapid Carb kit tests for carbapenemase detection. J Clin Microbiol 53:3539–3542. doi: 10.1128/JCM.01631-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hombach M, von Gunten B, Castelberg C, Bloemberg GV. 2015. Evaluation of the Rapidec Carba NP test for detection of carbapenemases in Enterobacteriaceae. J Clin Microbiol 53:3828–3833. doi: 10.1128/JCM.02327-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Dortet L, Agathine A, Naas T, Cuzon G, Poirel L, Nordmann P. 2015. Evaluation of the Rapidec Carba NP, the Rapid Carb Screen and the Carba NP test for biochemical detection of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 70:3014–3022. doi: 10.1093/jac/dkv213. [DOI] [PubMed] [Google Scholar]
  • 14.Garg A, Garg J, Upadhyay GC, Agarwal A, Bhattacharjee A. 2015. Evaluation of the Rapidec Carba NP test kit for detection of carbapenemase-producing Gram-negative bacteria. Antimicrob Agents Chemother 59:7870–7872. doi: 10.1128/AAC.01783-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lifshitz Z, Adler A, Carmeli Y. 2016. Comparative study of a novel biochemical assay, the Rapidec Carba NP test, for detecting carbapenemase-producing Enterobacteriaceae. J Clin Microbiol 54:453–456. doi: 10.1128/JCM.02626-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kabir MH, Meunier D, Hopkins KL, Giske CG, Woodford N. 2016. A two-centre evaluation of Rapidec Carba NP for carbapenemase detection in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. J Antimicrob Chemother 71:1213–1216. doi: 10.1093/jac/dkv468. [DOI] [PubMed] [Google Scholar]
  • 17.Bogaerts P, Yunus S, Massart M, Huang TD, Glupczynski Y. 2016. Validation of the BYG test version 2.0: an even more rapid and simplified protocol for laboratory detection of the carbapenemase-producing Enterobacteriaceae, abstr P3066 Abstr 26th Eur Congr Clin Micrbiol Infect Dis, Amsterdam, the Netherlands. [Google Scholar]
  • 18.Dortet L, Poirel L, Errera C, Nordmann P. 2014. CarbAcineto NP test for rapid detection of carbapenemase-producers in Acinetobacter spp. J Clin Microbiol 52:2359–2364. doi: 10.1128/JCM.00594-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI M100-S25 Clinical and Laboratory Standards Institute, Wayne, PA. [Google Scholar]
  • 20.Bogaerts P, Rezende de Castro R, de Mendonca R, Huang TD, Denis O, Glupczynski Y. 2013. Validation of carbapenemase and extended-spectrum beta-lactamase multiplex endpoint PCR assays according to ISO 15189. J Antimicrob Chemother 68:1576–1582. doi: 10.1093/jac/dkt065. [DOI] [PubMed] [Google Scholar]
  • 21.Nordmann P, Poirel L, Dortet L. 2012. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 18:1503–1507. doi: 10.3201/eid1809.120355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Rosco Diagnostica. 2014. Rapid Carb screen kit version 98024, package insert revision DBV0040K. Rosco Diagnostica A/S, Taastrup, Denmark. [Google Scholar]
  • 23.BioMérieux. 2015. Rapidec Carba NP, package insert version 20584. bioMérieux SA, Marcy-l'Etoile, France. [Google Scholar]
  • 24.Bio-Rad. 2015. Βeta-Carba test, package insert version 881159. Bio-Rad, Marnes-la-Coquette, France. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental material

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES